行情

ARDX

ARDX

Ardelyx
NASDAQ

实时行情|Nasdaq Last Sale

6.66
-0.20
-2.92%
盘前: 6.68 +0.02 +0.30% 08:50 03/05 EST
开盘
6.80
昨收
6.86
最高
6.95
最低
6.43
成交量
1.07万
成交额
--
52周最高
8.33
52周最低
4.220
市值
6.01亿
市盈率(TTM)
-6.5442
分时
5日
1月
3月
1年
5年
Ardelyx, Kyowa Kirin Highlight New Clinical Data Presented Within 5 Posters For Kidney Week 2020
Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company developing targeted, first-in-class medicines to improve the lives of patients with kidney and cardiovascular diseases, and Kyowa Kirin Co., Ltd. (Kyowa Kirin,
Benzinga · 2020/10/22 14:01
Ardelyx Highlights Presentation Of Tenapanor Data At ASN's Kidney Week 2020 Oct. 22-25
FREMONT, Calif., Oct. 12, 2020 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with kidney and
Benzinga · 2020/10/12 12:08
Ardelyx (NASDAQ:ARDX) Is Using Debt Safely
finviz · 2020/10/02 11:02
Ardelyx Inc (ARDX): Hedge Funds Are Snapping Up
finviz · 2020/09/29 15:23
Ardelyx Announces FDA Acceptance for Filing of its New Drug Application of Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis
finviz · 2020/09/15 12:00
Ardelyx to Participate in Three Upcoming Investor Conferences in September
finviz · 2020/09/08 12:00
Reflecting on Ardelyx's (NASDAQ:ARDX) Share Price Returns Over The Last Five Years
finviz · 2020/08/27 12:41
Ardelyx (ARDX) Reports Q2 Loss, Tops Revenue Estimates
finviz · 2020/08/06 15:45
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解ARDX最新的财务预测,通过ARDX每股收益,每股净资产,每股现金流等数据分析Ardelyx近期的经营情况,然后做出明智的投资选择。
分析师评级

8位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测ARDX价格均价为14.00,最高价位15.00,最低价为11.00。
EPS
机构持股
总机构数: 181
机构持股: 8,722.05万
持股比例: 96.64%
总股本: 9,024.85万
类型机构数股数
增持
35
284.96万
建仓
32
192.26万
减持
40
298.10万
平仓
0
0
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
-3.62%
制药与医学研究
-2.13%
高管信息
Chairman/Independent Director
David Mott
President/Chief Executive Officer/Director
Michael Raab
Chief Financial Officer/Chief Accounting Officer
Justin Renz
Chief Administrative Officer
Elizabeth Grammer
Other
Susan Rodriguez
Other
David Rosenbaum
Independent Director
Robert Bazemore
Independent Director
William Bertrand
Independent Director
Geoffrey Block
Independent Director
Onaiza Cadoret-Manier
Independent Director
Jan Lundberg
Independent Director
Gordon Ringold
Independent Director
Richard Rodgers
暂无数据
ARDX 简况
Ardelyx, Inc.是一家临床阶段的生物制药公司,专注于发现、开发和销售用于胃肠(GI)道治疗胃肠和心肾疾病的微创系统治疗药物。该公司主要从事研究、开发和销售生物制药产品业务。它已经发现并设计其主导候选产品,tenapanor。tenapanor是一种局部作用于胃肠道,用于抑制钠转运体钠/氢交换因子3(NHE3)并减少肠内钠和磷摄取的最小系统性小分子。它正于便秘型肠易激综合征(IBS-C)患者的两项关键III期临床研究中评估tenapanor。它正在开发用于治疗高钾血症的RDX022。RDX022是口服非吸收钾粘合剂。其开发项目还包括RDX009项目、RDX013项目和RDX011项目。

微牛提供Ardelyx Inc(NASDAQ-ARDX)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的ARDX股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易ARDX股票基本功能。